New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors

Andreas Kjaer (Opfinder), Morten Persson (Opfinder), Michael Ploug (Opfinder)

Fingeraftryk

Dyk ned i forskningsemnerne om 'New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors'. Sammen danner de et unikt fingeraftryk.

Kemiske forbindelser